Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Matthew Kurian

Breast Oncology · St Elizabeth Healthcare

View

Dr. Sarah Premji

Breast Oncology

View

Dr. Roberto Leon-Ferre

Breast Oncology · Mayo Clinic College of Medicine

View

Dr. Nerea Lopetegui-Lia

Breast Oncology · OSUMC

View

Dr. Allison Kurian

Breast Oncology · SU

View

Dr. Minhtri Nguyen

Breast Oncology · Advisor

View

Dr. Neil Iyengar

Breast Oncology · Emory University

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    STDr. Sara Tolaney
    Leading Voice

    Dr. Sara Tolaney

    Medical Oncology · Breast Oncology
    Dana-Farber Cancer Institute
    sarat

    Research

    Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer

    2026

    Via Clinical Cancer Research

    Research

    Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution

    2026

    Via Breast Cancer Research and Treatment

    Research

    Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

    2026

    Via Journal of Clinical Oncology

    Research

    Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors

    2025

    Via Journal of Precision Oncology

    Research

    Integration of Gene Expression and Digital Histology to Predict Treatment-Specific Responses in Breast Cancer

    2025

    Via medRxiv

    Research

    Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

    2025

    Via Cell Genomics

    Research

    APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer

    2025

    Via bioRxiv

    Research

    Clinical perspective on management of key adverse events with sacituzumab govitecan

    2025

    Via The Oncologist

    Research

    Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II study

    2025

    Via Breast Cancer Research

    Research

    Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment

    2025

    Via Nature Reviews Cancer

    Research

    Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial

    2025

    Via Nature Communications

    Research

    Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer

    2025

    Via Nature Communications

    Research

    A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancer

    2025

    Via Clinical Cancer Research

    Research

    Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer

    2025

    Via Journal of the National Cancer Institute

    Research

    Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database

    2025

    Via Breast Cancer Research and Treatment